Introduction {#sec1-1}
============

The incidence and mortality rates of stomach, liver, and cervical cancers are higher in lower-income countries than in higher-income countries (Ott et al., 2011). By contrast, those of lung, colorectal, and breast cancer are higher in higher-income countries (Torre et al., 2016). Individuals with higher levels of income and education are more likely to participate in cancer screening and treatment, thus explaining the lower rates of certain forms of cancer.

Meanwhile, risk factors for cancer include smoking, overweight and obesity, drinking, and certain chronic infections (Anand et al., 2008). Specifically, infections caused by Helicobacter pylori, human papillomavirus, and the hepatitis B and C viruses are the leading causes of stomach, cervical, and liver cancers, respectively (Oh et al., 2014). Previous studies reported that chronic infections are more likely to cause cancer in lower-income countries, further explaining differences in cancer incidence between lower- and higher-income nations (Ott et al., 2011; Bruni et al., 2016). Although the incidence of infection-related cancers declined in most higher-income countries, that of liver and stomach cancers is higher in Japan than in other countries (Ferlay et al., 2012).

In Japan, the overall incidence of cancer is increasing, and the disease has been a leading cause of death since 1981 (Vital statistics Japan). Specifically, the incidence of colorectal, lung, breast, pancreas, cervical, and prostate cancers has been increasing in Japan due to its aging society, although general cancer-related mortality has been decreasing (Vital statistics Japan). Some Japanese studies noted the inverse associations of cervical, endometrial, and colorectal cancer incidence and survival with area deprivation (Ueda et al., 2006; Miki et al., 2014). However, there have been few population-based studies of the association of area income with cancer death in Japan.

Aomori Prefecture has experienced the highest cancer-related mortality rates since the 2000s in Japan. Conversely, other prefectures successfully decreased cancer mortality rates. Thus, revealing the barriers to improving cancer-related mortality rates in Aomori Prefecture is of the utmost importance. It is assumed that access to hospitals and medical treatment may be an important factor in Aomori Prefecture because of its aging population and shortage of public transportation. In addition, the annual income of residents in Aomori Prefecture is lower than that of a countrywide average, 2,405,000 yen vs. 3,057,000 yen (System of National Accounts).

Aomori Prefecture consists of 40 municipal governments, and these regions have varied economic conditions (Supplement and supporting data). It is presumed that this inequality of economic conditions might be associated with cancer incidence and mortality. Therefore, the aims of this study were to examine the relationships of the incidence and mortality rates of common cancers (stomach, colorectal, liver, lung, breast, cervical, and prostate) in Japan with the income levels of the 40 municipalities in Aomori Prefecture and clarify the factors contributing to the high mortality rates in the prefecture.

Materials and Methods {#sec1-2}
=====================

Patients {#sec2-1}
--------

We included data on all patients diagnosed with stomach, colorectal, liver, lung, breast, cervical, or prostate cancer in the Aomori cancer registry database between 2010 and 2012, and the patients were followed up until December 2013. Death certificate only (DCO) cases were excluded. The percentage of DCO cases (%DCO) is one of the quality indicators of cancer registry data, and the %DCO values of the Aomori cancer registry for 2010, 2011, and 2012 were 5.1%, 2.6%, and 2.0%, respectively.

Data collection {#sec2-2}
---------------

We obtained the following clinical and demographic information via data extraction: sex, age at diagnosis, date of diagnosis, survival duration, primary tumor site (International Classification of Disease for Oncology, Third Edition; site code C16, C18--C20, C22, C33--C34, C50, C53, C61), stage at diagnosis, treatment administered (surgery, endoscopy, radiotherapy, chemotherapy, endocrine therapy, and other treatment), and address code. Stage at diagnosis was classified as in situ, localized (confined to the organ of origin), regional (invasion of adjacent organs or tissues and/or regional lymph node metastasis), distant (the presence of any distant metastasis), or unknown according to the Surveillance, Epidemiology, and End Results summary stage at diagnosis (Young et al., 2001). Income data for the 40 municipalities in 2010 were obtained from the Aomori Prefectural Government homepage (Municipal inhabitant's accounts statistics in Aomori prefecture), and income was classified into four groups by quartile as follows: lowest, mid-low, mid-high, and highest (Supplement and supporting data). The population of the municipalities in 2011--2012 was calculated using the interpolation method based on the population data of the National Census of Japan in 2010 and 2015 (National Census of Japan).

Statistical analysis {#sec2-3}
--------------------

Age-standardized incidence rates (AIRs) were calculated using the direct method based on the Japanese standard population. The incidence rate ratios (IRRs) were calculated using the lowest income area as the reference. The risk of cancer mortality related to economic disparities was determined via multivariable Cox regression analysis and adjusted for age, sex, and stage at diagnosis in the multivariable model. Hazard ratios (HRs) were calculated using Stata 13 statistical software (StataCorp LLP, College Station, TX, USA).

Results {#sec1-3}
=======

We identified 21,858 eligible patients, but the data for 618 patients were excluded for the following reasons: DCO, 616 cases; unknown address, 1 case; and unknown sex, 1 case.

[Table 1](#T1){ref-type="table"} presents the characteristics of patients with various cancer. The proportions of patients with stomach or colorectal cancer who were diagnosed at early and late stages were similar among the income groups, although treatment was not equitable among the groups. The proportions of patients with stomach or colorectal cancer who were treated with surgery, radiotherapy, and chemotherapy were higher in higher-income areas than in lower-income areas. However, the proportion of patients with stomach cancer who were treated with endoscopic therapy was highest in the lowest income area. A higher proportion of patients with liver cancer received chemotherapy in higher-income areas than in lower-income areas. The proportion of patients who received other treatments (percutaneous ethanol injection therapy, radiofrequency ablation, and hepatic transcatheter arterial chemoembolization) was higher in higher-income areas than in lower-income areas. No significant differences in stage at diagnosis according to income were noted among patients with lung cancer. However, the proportion of patients with lung cancer who were treated with chemotherapy increased with increasing income. Meanwhile, the proportion of patients with breast cancer who were diagnosed at an early stage (in situ or localized) was higher in higher-income areas than in lower-income areas. Additionally, the proportions of patients with breast cancer who were treated with radiotherapy and endocrine therapy were highest in the highest income area. Among patients with cervical cancer, the proportion of patients who were diagnosed at an early stage (in situ or localized) was lowest in the lowest income area, and the proportion of patients treated with surgery was higher in higher-income areas than in lower-income areas. Conversely, the proportion of patients treated with chemotherapy was lower in lower-income areas. Among patients with prostate cancer, patients in the highest income group were most likely to be diagnosed at an early stage (localized). Additionally, the proportion of patients who received radiotherapy was higher in higher-income areas than in lower-income areas.

###### 

Characteristics of Patients with Cancer

                            Stomach                                                                                   
  ------------------------- ---------------- -------------- ------------- ------------- ------- ------------- ------- ------
  Sex                                                                                                                 
   Men                      353              71.2           392           67.2          877     67.6          1,347   69.7
   Women                    143              28.8           191           32.8          420     32.4          586     30.3
  Age at diagnosis, years                                                                                             
   -59                      54               10.9           66            11.3          160     12.3          304     15.7
   60-69                    116              23.4           132           22.6          343     26.4          501     25.9
   70-79                    193              38.9           219           37.6          445     34.3          671     34.7
   80+                      133              26.8           166           28.5          349     26.9          457     23.6
  Stage at diagnosis                                                                                                  
   In situ                  9                1.8            6             1.0           4       0.3           3       0.2
   Localized                237              47.8           266           45.6          598     46.1          833     43.1
   Regional                 97               19.6           119           20.4          243     18.7          462     23.9
   Distant                  90               18.1           126           21.6          282     21.7          428     22.1
   Unknown                  63               12.7           66            11.3          170     13.1          207     10.7
  Surgical treatment                                                                                                  
   Surgery                  214              43.1           280           48.0          631     48.7          969     50.1
   Non-surgery              235              47.4           274           47.0          593     45.7          871     45.1
   Unknown                  47               9.5            29            5.0           73      5.6           93      4.8
  Endoscopic therapy                                                                                                  
   Endoscopic therapy       121              24.4           105           18.0          224     17.3          363     18.8
   Non-endoscopic therapy   333              67.1           447           76.7          994     76.6          1,473   76.2
   Unknown                  42               8.5            31            5.3           79      6.1           97      5.0
  Radiotherapy treatment                                                                                              
   Radiotherapy             1                0.2            5             0.9           12      0.9           17      0.9
   Non-radiotherapy         444              89.5           548           94            1,208   93.1          1,819   94.1
   Unknown                  51               10.3           30            5.1           77      5.9           97      5.0
                                                                                                                      
                            **Colorectal**                                                                            
  **Lowest**                **Mid-low**      **Mid-high**   **Highest**                                               
  **n=664**                                  **n=810**                    **n=1885**            **n=3119**            
                                                                                                                      
  Sex                                                                                                                 
   Men                      382              57.5           483           59.6          1071    56.8          1785    57.2
   Women                    282              42.5           327           40.4          814     43.2          1334    42.8
  Age at diagnosis, years                                                                                             
   -59                      121              18.2           108           13.3          338     17.9          514     16.5
   60-69                    154              23.2           213           26.3          501     26.6          879     28.2
   70-79                    219              33             293           36.2          620     32.9          1079    34.6
   80+                      170              25.6           196           24.2          426     22.6          647     20.7
  Stage at diagnosis                                                                                                  
   In situ                  139              20.9           166           20.5          341     18.1          620     19.9
   Localized                191              28.8           244           30.1          585     31            1032    33.1
   Regional                 135              20.3           176           21.7          429     22.8          690     22.1
   Distant                  104              15.7           148           18.3          334     17.7          515     16.5
   Unknown                  95               14.3           76            9.4           196     10.4          262     8.4
   Surgery                  359              54.1           512           63.2          1,168   62.0          2,000   64.1
   Non-surgery              212              31.9           250           30.9          612     32.5          972     31.2
   Unknown                  93               14.0           48            5.9           105     5.6           147     4.7
  Endoscopic therapy                                                                                                  
   Endoscopic therapy       169              25.5           166           20.5          404     21.4          721     23.1
   Non-endoscopic therapy   426              64.2           591           73.0          1,371   72.7          2229    71.5
   Unknown                  69               10.4           53            6.5           110     5.8           169     5.4
  Radiotherapy treatment                                                                                              
   Radiotherapy             2                0.3            3             0.4           12      0.6           27      0.9
   Non-radiotherapy         560              84.3           754           93.1          1758    93.3          2913    93.4
   Unknown                  102              15.4           53            6.5           115     6.1           179     5.7
                                                                                                                      
                            **Liver**                                                                                 
  **Lowest**                **Mid-low**      **Mid-high**   **Highest**                                               
  **n=124**                                  **n=169**                    **n=433**             **n=566**             
                                                                                                                      
  Sex                                                                                                                 
   Men                      84               67.7           107           63.3          291     67.2          376     66.4
   Women                    40               32.3           62            36.7          142     32.8          190     33.6
  Age at diagnosis, years                                                                                             
   -59                      22               17.7           18            10.7          62      14.3          73      12.9
   60-69                    39               31.5           39            23.1          100     23.1          159     28.1
   70-79                    39               31.5           70            41.4          149     34.4          189     33.4
   80+                      24               19.4           42            24.9          122     28.2          145     25.6
  Stage at diagnosis                                                                                                  
   Localized                57               46             93            55            218     50.3          262     46.3
   Regional                 17               13.7           27            16            81      18.7          101     17.8
   Distant                  20               16.1           25            14.8          49      11.3          77      13.6
   Unknown                  30               24.2           24            14.2          85      19.6          126     22.3
  Surgical treatment                                                                                                  
   Surgery                  20               16.1           30            17.8          41      9.5           63      11.1
   Non-surgery              87               70.2           130           76.9          346     79.9          434     76.7
   Unknown                  17               13.7           9             5.3           46      10.6          69      12.2
  Radiotherapy treatment                                                                                              
   Radiotherapy             1                0.8            3             1.8           2       0.5           11      1.9
   Non-radiotherapy         106              85.5           157           92.9          385     88.9          484     85.5
   Unknown                  17               13.7           9             5.3           46      10.6          71      12.5
  Other treatment                                                                                                     
   Yes                      51               41.1           58            34.3          194     44.8          248     43.8
   No                       56               45.2           102           60.4          193     44.6          248     43.8
   Unknown                  17               13.7           9             5.3           46      10.6          70      12.4
                                                                                                                      
                            **Lung**                                                                                  
  **Lowest**                **Mid-low**      **Mid-high**   **Highest**                                               
  **n=434**                                  **n=472**                    **n=1,062**           **n=1,700**           
                                                                                                                      
  Sex                                                                                                                 
   Men                      320              73.7           334           70.8          745     70.2          1,198   70.5
   Women                    114              26.3           138           29.2          317     29.8          502     29.5
  Age at diagnosis, years                                                                                             
   -59                      55               12.7           44            9.3           106     10            208     12.2
   60-69                    89               20.5           116           24.6          258     24.3          467     27.5
   70-79                    155              35.7           175           37.1          405     38.1          602     35.4
   80+                      135              31.1           137           29.0          293     27.6          423     24.9
  Stage at diagnosis                                                                                                  
   In situ                  1                0.2            0             0.0           1       0.1           1       0.1
   Localized                105              24.2           110           23.3          198     18.6          391     23.0
   Regional                 100              23.0           121           25.6          250     23.5          404     23.8
   Distant                  152              35.0           169           35.8          437     41.1          642     37.8
   Unknown                  76               17.5           72            15.3          176     16.6          262     15.4
  Surgical treatment                                                                                                  
   Surgery                  90               20.7           98            20.8          207     19.5          439     25.8
   Non-surgery              293              67.5           326           69.1          745     70.2          1,100   64.7
   Unknown                  51               11.8           48            10.2          110     10.4          161     9.5
  Radiotherapy treatment                                                                                              
   Radiotherapy             108              24.9           116           24.6          214     20.2          416     24.5
   Non-radiotherapy         276              63.6           305           64.6          739     69.6          1122    66.0
   Unknown                  50               11.5           51            10.8          109     10.3          162     9.5
                                                                                                                      
                            **Breast**                                                                                
  **Lowest**                **Mid-low**      **Mid-high**   **Highest**                                               
  **n=186**                                  **n=272**                    **n=711**             **n=1,456**           
                                                                                                                      
  Sex                                                                                                                 
   Men                      2                1.1            3             1.1           4       0.6           12      0.8
   Women                    184              98.9           269           98.9          707     99.4          1,444   99.2
  Age at diagnosis, years                                                                                             
   -59                      84               45.2           143           52.6          362     50.9          750     51.5
   60-69                    45               24.2           70            25.7          181     25.5          366     25.1
   70-79                    36               19.4           42            15.4          108     15.2          225     15.5
   80+                      21               11.3           17            6.3           60      8.4           115     7.9
  Stage at diagnosis                                                                                                  
   In situ                  15               8.1            15            5.5           75      10.5          132     9.1
   Localized                89               47.8           140           51.5          365     51.3          774     53.2
   Regional                 52               28             70            25.7          169     23.8          366     25.1
   Distant                  8                4.3            15            5.5           43      6             79      5.4
   Unknown                  22               11.8           32            11.8          59      8.3           105     7.2
  Surgical treatment                                                                                                  
   Surgery                  154              82.8           208           76.5          596     83.8          1179    81
   Non-surgery              16               8.6            40            14.7          79      11.1          201     13.8
   Unknown                  16               8.6            24            8.8           36      5.1           76      5.2
  Radiotherapy treatment                                                                                              
   Radiotherapy             36               19.4           49            18            152     21.4          547     37.6
   Non-radiotherapy         134              72             197           72.4          522     73.4          828     56.9
   Unknown                  16               8.6            26            9.6           37      5.2           81      5.6
  Endocrine treatment                                                                                                 
   Endocrinotherapy         71               38.2           81            29.8          227     31.9          810     55.6
   Non-endocrinotherapy     99               53.2           164           60.3          446     62.7          566     38.9
   Unknown                  16               8.6            27            9.9           38      5.3           80      5.5
                                                                                                                      
                            **Cervical**                                                                              
  **Lowest**                **Mid-low**      **Mid-high**   **Highest**                                               
  **n=76**                                   **n=109**                    **n=299**             **n=601**             
                                                                                                                      
  Sex                                                                                                                 
   Women                    76               100            109           100           299     100           601     100
  Age at diagnosis, years                                                                                             
   -59                      58               76.3           86            78.9          244     81.6          500     83.2
   60-69                    8                10.5           12            11            21      7.0           53      8.8
   70-79                    6                7.9            9             8.3           18      6.0           33      5.5
   80+                      4                5.3            2             1.8           16      5.4           15      2.5
  Stage at diagnosis                                                                                                  
   In situ                  44               57.9           75            68.8          204     68.2          401     66.7
   Localized                16               21.1           17            15.6          36      12.0          88      14.6
   Regional                 13               17.1           12            11            32      10.7          56      9.3
   Distant                  2                2.6            4             3.7           15      5.0           25      4.2
   Unknown                  1                1.3            1             0.9           12      4.0           31      5.2
  Surgical treatment                                                                                                  
   Surgery                  58               76.3           97            89            246     82.3          491     81.7
   Non-surgery              12               15.8           10            9.2           42      14.0          76      12.6
   Unknown                  6                7.9            2             1.8           11      3.7           34      5.7
  Radiotherapy treatment                                                                                              
   Radiotherapy             12               15.8           10            9.2           39      13.0          72      12.0
   Non-radiotherapy         57               75             96            88.1          243     81.3          466     77.5
   Unknown                  7                9.2            3             2.8           17      5.7           63      10.5
                                                                                                                      
                            **Prostate**                                                                              
  **Lowest**                **Mid-low**      **Mid-high**   **Highest**                                               
  **n=169**                                  **n=220**                    **n=502**             **n=892**             
                                                                                                                      
  Sex                                                                                                                 
   Men                      169              100            220           100           502     100           892     100
  Age at diagnosis, years                                                                                             
   -59                      9                5.3            13            5.9           29      5.8           53      5.9
   60-69                    53               31.4           76            34.5          140     27.9          258     28.9
   70-79                    78               46.2           89            40.5          249     49.6          433     48.5
   80+                      29               17.2           42            19.1          84      16.7          148     16.6
  Stage at diagnosis                                                                                                  
   In situ                  \-                              \-                          \-                    \-      
   Localized                85               68.5           101           59.8          261     60.3          501     88.5
   Regional                 35               28.2           47            27.8          101     23.3          138     24.4
   Distant                  12               9.7            23            13.6          75      17.3          122     21.6
   Unknown                  37               29.8           49            29            65      15            131     23.1
  Surgical treatment                                                                                                  
   Surgery                  53               31.4           56            25.5          126     25.1          228     25.6
   Non-surgery              87               51.5           124           56.4          319     63.5          537     60.2
   Unknown                  29               17.2           40            18.2          57      11.4          127     14.2
  Radiotherapy treatment                                                                                              
   Radiotherapy             20               11.8           32            14.5          104     20.7          165     18.5
   Non-radiotherapy         121              71.6           148           67.3          341     67.9          601     67.4
   Unknown                  28               16.6           40            18.2          57      11.4          126     14.1
  Endocrine treatment                                                                                                 
   Endocrinotherapy         76               45             96            43.6          264     52.6          462     51.8
   Non-endocrinotherapy     69               40.8           85            38.6          182     36.3          308     34.5
   Unknown                  24               14.2           39            17.7          56      11.2          122     13.7

[Table 2](#T2){ref-type="table"} shows the AIRs and IRRs by income and cancer type. [Figure 1](#F1){ref-type="fig"} shows scatter plot between AIRs and residential income. There were no differences in AIRs and IRRs among patients with stomach, colorectal, or lung cancer according to income. Contrarily, AIRs and IRRs were higher in higher-income areas than in lower-income areas among patients with breast, cervical, or prostate cancer.

###### 

Age-Standardized Incidence Rates (AIRs) and Incidence Rate Ratios (IRRs) for Various Cancers

                       Stomach   Colorectal   Liver           Lung          Breast   Cervical        Prostate                                                                                                                                                                                 
  -------------------- --------- ------------ --------------- ------------- -------- --------------- ------------- ------ ---------------- ------------- ------ --------------- ------------- ------ -------------- ------------- ------ --------------- ------------- ------ --------------- -------------
  Residential income   Lowest    47.2         1.0             (reference)   71.5     1.0             (reference)   13.2   1.0              (reference)   40.9   1.0             (reference)   61.8   1.0            (reference)   43.4   1.0             (reference)   36.6   1.0             (reference)
  Mid-low              53.1      1.1          (−0.8 to 7.0)   77.4          1.1      (−0.3 to 6.2)   15.4          1.2    (−4.1 to 10.5)   41.7          1.0    (−1.5 to 7.1)   88.1          1.4    (0.9 to 7.4)   57.3          1.3    (−0.2 to 7.7)   46.9          1.3    (−0.7 to 7.9)   
  Mid-high             51.3      1.1          (−1.0 to 6.9)   79.9          1.1      (−0.1 to 6.3)   16.9          1.3    (−3.6 to 10.8)   40.0          1.0    (−1.7 to 7.0)   86.6          1.4    (0.8 to 7.3)   58.4          1.3    (−0.1 to 7.8)   45.0          1.2    (−0.9 to 7.8)   
  Highest              47.8      1.0          (−1.3 to 6.8)   78.9          1.1      (−0.2 to 6.2)   13.5          1.0    (−4.8 to 10.3)   40.3          1.0    (−1.7 to 7.0)   101.8         1.6    (2.0 to 8.3)   62.8          1.4    (0.4 to 8.1)    47.6          1.3    (−0.6 to 8.0)   

IRR, incidence rate ratio; CI, confidence interval

![Scatter Plots between AIRs and Residential Income for Various Cancers.](APJCP-19-3193-g001){#F1}

[Table 3](#T3){ref-type="table"} presents the adjusted HRs for each income category. Although the adjusted HRs tended to be highest in the lowest income area, there were no significant differences according to income for any cancer type.

###### 

Adjusted Hazard Ratios (HRs) for Various Cancers

                       Stomach   Colorectal       Liver         Lung   Breast           Cervical      Prostate                                                                                                                                                                                          
  -------------------- --------- ---------------- ------------- ------ ---------------- ------------- ---------- ---------------- ------------- ------ ---------------- ------------- ------ ---------------- ------------- ------ ---------------- ------------- ------ ---------------- ------------- --
  Residential income   Lowest    1                (reference)          1                (reference)              1                (reference)          1                (reference)          1                (reference)          1                (reference)          1                (reference)   
  Mid-low              0.97      (0.81 to 1.16)   0.72          1.07   (0.89 to 1.02)   0.46          0.86       (0.64 to 1.16)   0.34          1.09   (0.92 to 1.29)   0.31          0.71   (0.38 to 1.31)   0.27          0.72   (0.29 to 1.79)   0.48          0.65   (0.41 to 1.02)   0.06          
  Mid-high             0.89      (0.75 to 1.04)   0.14          0.95   (0.81 to 1.12)   0.56          0.73       (0.57 to 0.94)   0.01          1.06   (0.92 to 1.22)   0.45          1.08   (0.65 to 1.81)   0.77          0.77   (0.38 to 1.57)   0.47          0.7    (0.48 to 1.03)   0.07          
  Highest              1         (0.86 to 1.17)   0.99          1.02   (0.87 to 1.18)   0.84          0.85       (0.67 to 1.08)   0.19          1.18   (1.03 to 1.35)   0.02          0.91   (0.56 to 1.49)   0.71          0.57   (0.28 to 1.16)   0.12          0.82   (0.57 to 1.16)   0.26          

Adjusted for age, sex, and stage at diagnosis.; CI, confidence interval

Discussion {#sec1-4}
==========

Certain chronic infections are risk factors for cancer, and they can explain variations in cancer incidence among low-, middle-, and high-income countries. A study by Ott et al. clearly indicated that the AIRs and mortality rates of lung, colorectal, and breast cancers were higher in high-income countries than in low- and middle-income countries (Ott et al., 2011). Moreover, they said that the AIRs and mortality rates of infection-related cancers (stomach, liver, and cervical cancers) were higher in low- and middle-income than in high-income countries (Ott et al., 2011). This can be explained by the fact that infection-related cancers account for more than 26% of the total cancers in low- and middle-income countries (Parkin et al., 2006). Conversely, the incidence rate of non-infection-related cancers has continued to increase in many countries including high-, middle-, and low-income countries (Global Burden of Disease Cancer Collaboration, et al., 2015). This unfavorable increase reflects an increased prevalence of known risk factors (e.g., obesity, physical inactivity, smoking) and the increased use of screening modalities (e.g., mammography, pap smear). Although mammography is the most effective method for detecting breast cancer at an early stage, it also leads to overdiagnosis of the disease (Marmot et al., 2013). A recent study that estimated that the rate of overdiagnosis due to mammography ranged 0%--54% (Puliti et al., 2011). By contrast, cancer-related mortality is affected by patients' access to cancer treatment. Because cancer treatment is not adequately accessible in low-income countries, cancer-related mortality rates have not declined in these countries (Fidler et al., 2017).

Our data identified disparities of AIRs for breast, cervical, and prostate cancers according to income, whereas those of stomach, colorectal, lung, and liver cancers were not influenced by income. However, the adjusted HRs were not significantly different according to income. Recent study investigated socioeconomic inequality in cancer mortality in South Korea (Khang et al., 2016). In this study, poor people had higher risk of cancer death. Although South Korea is similar to Japan, our results differed from previous study. These findings can be explained by several factors. First, the prevalence of risk factors for cervical, breast, and prostate cancers was higher in high-income areas than in middle- and low-income areas. Risk factors for these cancers include HPV infection, alcohol consumption habit, obesity, and aging (Key et al., 2002). In Aomori Prefecture, the average BMI among women was 23.2 in 2012, compared with a countrywide average of 22.5 (National Health and Nutrition Survey in 2012). In addition, 30.1% of people in Aomori Prefecture are older than 65, compared with 26.6% for the entire country (National Census of Japan). This higher proportion of elderly people might explain the findings in the prefecture. Second, because there were no significant differences in adjusted HRs according to age, overdiagnosis due to easy access to hospitals would increase the incidence rates and overtreatment for patients with breast, cervical, and prostate cancers simultaneously in higher-income areas. Several studies have underlined the problems of overdiagnosis and overtreatment (Nagler et al., 2017; Morgan et al., 2017; Jegerlehner et al., 2017). The Norwegian Breast Cancer Screening Program was conducted in 1995 and 1996 (Falk et al., 2013). This study reported the frequency of overdiagnosis among a cohort of women over a period of 10 years after they participated in cancer screening. Falk et al. estimated the number of women overdiagnosed in mammographic screening using English, Welsh, and Norwegian data (Falk et al., 2016). Moreover, Kilpeläinen et al., (2016) reported the association of prostate cancer with socioeconomic status in Finland. Their study found that higher socioeconomic status was associated with the overdiagnosis of low-risk prostate cancer, as well as a lower risk of incurable prostate cancer and lower prostate cancer-related mortality. Unnecessary treatment, higher treatment costs, and otiose anxiety might be burdensome to patients. Third, it was suspected that accessibility to cancer treatment was not significantly affected by residential income. Dreyer et al., (2017) reported socioeconomic disparities in the receipt of treatment for incident breast cancer. They observed that poor and near-poor women were less likely to receive treatment than women of a higher socioeconomic status. Kumachev et al., (2016) studied the associations among socioeconomic status, screening, and treatments. In this study, they demonstrated that higher socioeconomic status was associated with greater frequencies of screening and treatments and higher survival rates. Therefore, our results partially coincided with these previous findings. However, age standardized mortality rates for cancer in Aomori Prefecture are the highest in Japan. Thus, the quality of cancer treatment might not be sufficient to decrease the number of cancer-related deaths in this region.

Our study had several limitations. First, the income data do not exactly reflect patients' individual income. Our data reflected the average annual income in municipal areas. However, residential income might not reflect access to health and medical services for cancer because local governments have a responsibility to formulate cancer policy and ensure cancer control. Second, we did not include data for cancer risk factors at the individual level. Third, we did not include patients' individual educational levels and occupations. These socioeconomic factors have been examined to explain the disparities regarding cancer incidence and death. Because this study was designed to clarify the effect of income disparities on cancer, we did not include these data.

In conclusion, the relationships of mean residential income with cancer incidence and mortality differed from previous findings. Patients with higher income were diagnosed with early-stage disease more frequently, and they had higher AIRs for breast, cervical, and prostate cancers than those with middle and low incomes. However, there were no significant differences in cancer survival rates. Our results might be helpful for policymakers to develop a cancer policy. Policymakers should take steps HPV infection control and stopping excess prostatic specific antigen test in higher income area. Although the associations of socioeconomic status with cancer incidence and mortality have been reported for developed countries, socioeconomic disparities exist among individual areas in the countries. The differences in cancer mortality rates between affluent and poor individuals have reportedly widened in high-income countries. Thus, inequalities of cancer mortality rates between affluent and poor areas should be also investigated.
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